ATLANTA, July 19, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces the appointment of John Snisarenko to its Board of Directors. Mr. Snisarenko has more than 30 years of commercial experience in the pharmaceutical industry, including major retina and ophthalmology businesses...